AI and Global Alliance Target Rare Childhood Cancers in £5.25M Push

OXFORD, UK and CLEVELAND, Ohio, US – July 01, 2026

A landmark £5.25 million partnership is set to redefine the fight against rare childhood cancers, uniting cutting-edge artificial intelligence with a transatlantic alliance of scientific and philanthropic power. The initiative, announced today, sees the University of Oxford and The Little Princess Trust join forces to expand the rare paediatric cancer programme at the Oxford-Harrington Rare Disease Centre (OHC).

At the heart of this strategic push is the appointment of Professor Isidro Cortés-Ciriano, an international leader in computational cancer genomics, as the first Little Princess Trust Professor of Paediatric Oncology. His role will be to spearhead a new research program designed to accelerate the journey from laboratory discovery to life-saving therapies for children with the most challenging cancers.

This collaboration marks a pivotal moment, combining the academic prowess of Oxford, the drug development machinery of the US-based Harrington Discovery Institute, and the focused philanthropic drive of The Little Princess Trust, the UK's second-largest funder of childhood cancer research. The goal is clear: to change the grim prognosis for thousands of children diagnosed each year with rare and aggressive cancers for whom treatment options are currently scarce.

The Architect of a New Approach

The appointment of Professor Isidro Cortés-Ciriano signals a strategic shift towards a data-driven, technologically advanced assault on paediatric cancer. Moving from his previous role at the prestigious European Molecular Biology Laboratory (EMBL-EBI) in Cambridge, Prof. Cortés-Ciriano brings a formidable arsenal of expertise in using computational biology and artificial intelligence to decode the complexities of cancer.

His research is not about abstract theory; it's about building practical tools to dismantle cancer's defenses. His team has developed novel algorithms to analyze the vast amounts of data generated by genome sequencing, identifying patterns of mutation and chromosomal chaos that drive cancer's growth. One of his group's key discoveries, a catastrophic event called Loss-Translocation-Amplification (LTA) chromothripsis, revealed a mechanism for rapid cancer transformation in bone cancers. By understanding how a cancer cell’s genome shatters and reassembles, scientists can devise smarter ways to attack it.

“Children with cancer deserve more effective, less toxic treatment options and better outcomes,” Prof. Isidro Cortés-Ciriano said. “What excites me the most about this opportunity is the ability to bring together expertise across cancer biology, data science, drug development and clinical research to accelerate the translation of scientific discoveries into novel therapies that can make a meaningful difference for patients and families.”

This work, which earned him a highly competitive €2 million ERC Consolidator Grant in 2025, will now be focused on the unique challenges of paediatric cancers. He will lead a new program at Oxford's Department of Paediatrics while also providing scientific leadership for the OHC's broader Cancer Theme, ensuring his computational insights are integrated across the centre's research into brain tumours, Hodgkin lymphoma, and blood cancers.

A Global Alliance Forged in Hope

This initiative is about more than one brilliant scientist; it is a testament to the power of strategic collaboration. The Oxford-Harrington Rare Disease Centre itself is a unique model, a bridge across the Atlantic designed to solve a fundamental problem in medicine: the "valley of death" where promising scientific discoveries languish for lack of funding and development expertise. The OHC pairs Oxford’s world-leading discovery science with the Harrington Discovery Institute's proven infrastructure for turning those discoveries into patient-ready medicines.

The infusion of £5.25 million from The Little Princess Trust provides the critical fuel for this engine. The charity, widely known for providing free, real-hair wigs to children who have lost their hair, has quietly become a powerhouse in research funding. Since 2016, it has committed funds to over 165 projects, evolving its mission from providing comfort to actively funding the cure.

Wendy Tarplee-Morris, MBE, Co-founder of The Little Princess Trust, articulated the vision behind the investment. “Every child diagnosed with cancer deserves better treatment options and the best possible future," she said. "By benefitting from access to world-class cancer research in Oxford and drug development expertise at the Harrington Discovery Institute in the US, the newly appointed Chair of Paediatric Oncology will accelerate the discovery of new medicines for children and families who urgently need them."

This transatlantic partnership provides a clear pathway. A discovery made in an Oxford lab can be rapidly validated and then advanced by the teams in Cleveland, which include experts at the University Hospitals Seidman Cancer Center and the renowned University Hospitals Rainbow Babies & Children's Hospital.

“Childhood cancers present some of the most difficult challenges in medicine requiring specialist expertise, innovative science and long-term commitment,” said Prof. Matthew Wood, Director and Chief Scientific Officer of the OHC. “This support allows us to do exactly that.”

Tackling the Unseen Battlefield

The urgency of this initiative is rooted in a stark reality. While survival rates for some common childhood cancers have improved dramatically, cancer remains a leading cause of disease-related death in children globally. In the UK and US alone, around 20,000 children and young people are diagnosed annually. For those with rare, aggressive, or relapsed cancers, the future remains uncertain, with treatments that are often decades old, highly toxic, and ineffective.

Rare diseases, by definition, affect a small number of patients, which often discourages commercial investment in research and development. This new program directly confronts that market failure. By pooling resources and focusing on the underlying biology of these diseases, the OHC aims to create a sustainable pipeline for new therapies.

The focus on "less toxic" treatments is a critical component. Many children who survive cancer suffer from long-term health problems—including secondary cancers, heart problems, and developmental issues—caused by the very chemotherapy and radiation that saved their lives. The precision promised by genomic medicine, guided by the computational insights of Prof. Cortés-Ciriano’s team, offers hope for therapies that target cancer cells specifically, leaving healthy cells unharmed.

Matthew Anderson, MD, PhD, Co-Director of the OHC, emphasized this translational focus. “Too many children with cancer still face limited treatment options. Closing that gap requires not only discovery, but the ability to translate science into medicines," he stated. "This gift strengthens our Cancer Theme and the Centre’s translational capabilities... with the aim of advancing new therapies to patients more quickly.”

The appointment and the partnership represent a multi-pronged attack on rare paediatric cancer, leveraging big data, international collaboration, and dedicated philanthropy to bring hope to families who have waited far too long for a breakthrough.